Fig 1: Combined damage to dopamine neurons and the occurrence of neurodegeneration among CTLA-4 and PD-1 blocker treated mice. Immunofluorescence showed that CTLA-4 and PD-1 blockers activated microglial activity in DBA/1 under DEN stimulation, and M1 type microglia were increased, M2 type microglia were decreased (A). TH staining showed that compared with the DD group, the number of dopamine neurons in the DDCP group was decreased (B). Tunel staining assay demonstrated that compared with the DD group, the apoptosis rate of substantia nigra neurons was increased in the DDCP group (C). *Indicated P<0.05 compared with DD group; #Indicated P<0.05 compared with CD group. n=10.
Fig 2: Kaplan–Meier survival analysis of CTLA4 and OX40L in tumor and tumor-adjacent stroma. Comparisons include high and low expression of CTLA4 (A) and OX40L (B). Quantized percent positivity from a series of TMA cores (n = 1547) was calculated using QuPath. Using a pretrained model, QuPath separated cells into determinants of either tumor or TAS tissue. This expression quantization was then provided as an input for Kaplan–Meier survival models. For both CTLA4 and OX40L, we identified significant differences in relation to biochemical relapse free (BCRF) survival in different tissue types. In tumor cells, high expression of CTLA4 was correlated with a lower overall BCRF survival. However, in tumor-adjacent stroma, high expression of CTLA4 was instead correlated with higher overall BCRF survival. These trends also held true for OX40L expression in both tumor and tumor-adjacent stroma. TMA = tissue microarray; TAS = tumor-adjacent stroma.
Fig 3: Validation and immune infiltration analysis. (A) ROC of mRNAs in the ceRNA network. (B) The differential of immune infiltration between the UC and normal groups. (C) Correlation matrix of immune cell proportions and CTLA4. (D) Lollipop chart of the correlation between immune cells and CTLA4. * p < 0.05, ** p < 0.01.
Fig 4: The relative expression was validated via qRT-PCR. (A) Hub mRNAs Related to CTLA4 in PPI. The relative expression of Miat (B), Clta4 (C), Fyn (D), Igtb2 (E), and Itk (F) in DSS-induced mice and Normal mice. (G) Representative immunofluorescence image of CTLA4 between DSS-induced mice and Normal mice. Red, Ctla4; blue, DAPI nuclear staining (n = 6/group). (H) Representative western blot image of Ctla4 between DSS-induced mice and Normal mice. (I) Quantification of western blot analysis. Dates are shown as mean ± SD. ** p < 0.01, *** p < 0.001.
Fig 5: Protein expression analysis in tumor and TAS tissue across 4 prostate cancer patients. Box plot depicting the protein expression levels of OX40L, CTLA4, and CD11c. These genes all had significant differences between tumor and TAS. OX40L and CTLA4 were the only two proteins that were upregulated in tumor adjacent stroma compared to tumor. Each dot represents an ROI. TAS = tumor-adjacent stroma; ROI = region of interest.
Supplier Page from Abcam for Anti-CTLA4 antibody [CAL49]